icon-folder.gif   Conference Reports for NATAP  
 
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Back grey_arrow_rt.gif
 
 
 
Hepatitis C Treatment Outcomes and Predictors of Response in Treatment-naive Patients Treated with Peginterferon Alfa/Ribavirin in Real-world Italian Clinics Compared with Other Countries: PROPHESYS Sub-analysis
 
 
  Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
 
A. Ascione,1 S. Bruno,2 C. Coppola,3 A. Mangia,4 A. Orlandini,5 M. Schmitz,6 B. Deodato,7 M. Puoti8; on behalf of the PROPHESYS 2 study group 1Centre for Liver Disease, Fatebenefratelli Hospital, Naples, Italy; 2Azienda Ospedaliera Fatebenefratelli e Oftalmico, Milan, Italy; 3Unita Operativa di Epatologia ed Ecografia Interventistica Ospedale Gragnano, Naples, Italy; 4IRCCS Hospital 'Casa Sollievo della Sofferenza', San Giovanni Rotondo, Italy; 5Azienda Ospedaliero-Universitaria di Parma, Parma, Italy; 6IST GmbH, Mannheim, Germany; 7Roche SpA, Monza, Italy; 8University of Brescia, Brescia, Italy

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif